Silexion Therapeutics
SLXN
4 hedge funds and large institutions have $17.3K invested in Silexion Therapeutics in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 6 closing their positions.
0.05% more ownership
Funds ownership: 0.02% → 0.07% (+0.05%)
50% less funds holding
Funds holding: 8 → 4 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
93% less capital invested
Capital invested by funds: $258K → $17.3K (-$241K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MA
Montag & Associates
Atlanta,
Georgia
|
+$24.9K |
| 2 |
PK
Pflug Koory
Omaha,
Nebraska
|
+$2.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Wildcat Capital Management
New York
|
-$91.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$54.7K |
| 3 |
MHC
Meyer Handelman Company
Rye Brook,
New York
|
-$26.7K |
| 4 |
MSAM
Moloney Securities Asset Management
Manchester,
Missouri
|
-$16.2K |
| 5 |
VF
Virtu Financial
New York
|
-$12K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MA
1
Montag & Associates
Atlanta,
Georgia
| $10.2K | +$24.9K | +300 | New |
|
|
SS
2
SBI Securities
Tokyo,
Japan
| $3.6K | -$249 | -3 | -3% |
|
|
3
UBS Group
Zurich,
Switzerland
| $2.35K | -$54.7K | -659 | -91% |
|
|
PK
4
Pflug Koory
Omaha,
Nebraska
| $1.13K | +$2.74K | +33 | New |
|
|
WCM
5
Wildcat Capital Management
New York
| – | -$91.9K | -756 | Closed |
|
|
MHC
6
Meyer Handelman Company
Rye Brook,
New York
| – | -$26.7K | -220 | Closed |
|
|
MSAM
7
Moloney Securities Asset Management
Manchester,
Missouri
| – | -$16.2K | -133 | Closed |
|
|
VF
8
Virtu Financial
New York
| – | -$12K | -95 | Closed |
|
|
SG
9
StoneX Group
New York
| – | -$9.11K | -75 | Closed |
|
10
Bank of America
Charlotte,
North Carolina
| – | -$405 | -3 | Closed |
|
SLXN Hedge Fund Activity: Q3 2025 in Review
4 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics (SLXN) for Q3 2025, worth a combined $17.3K — down 93% from $258K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SLXN and 2 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 0 added.
The largest buyer was Montag & Associates, opening a new position worth an estimated $24.9K. The largest seller was Wildcat Capital Management, exiting entirely with an estimated $91.9K sold.
- 4 institutional investors held Silexion Therapeutics (SLXN) as of Q3 2025, down from 8 in Q2 2025.
- Funds reported $17.3K of Silexion Therapeutics stock for Q3 2025, down 93% quarter-over-quarter.
- 2 funds opened new Silexion Therapeutics positions in Q3 2025 and 6 closed out, a net change of -4 holders.
- The largest Silexion Therapeutics buyer in Q3 2025 was Montag & Associates, an estimated $24.9K added.
- The largest Silexion Therapeutics seller in Q3 2025 was Wildcat Capital Management, an estimated $91.9K sold.
Based on aggregated 13F filings for Q3 2025.